Medicine and Dentistry
Actinic Keratosis
36%
Age
8%
Analysis
53%
Apremilast
36%
Biopsy
6%
Bone Marrow Biopsy
6%
Chemotherapeutic Agent
36%
Chemotherapy
6%
Combination Therapy
36%
Comprehension
6%
Contraindication
6%
Dermatology
36%
Diagnosis
6%
Diseases
23%
Drug
36%
Electron Therapy
6%
Enalapril Maleate
6%
Evolution
36%
Female
5%
Gamma Delta T-Cell
6%
Immunosuppressive Drug
6%
Immunosuppressive Treatment
6%
Inpatient
48%
Kidney Transplantation
36%
Lymph Duct
6%
Mycosis fungoides
36%
Neoplasm
6%
Observation
5%
Organ
6%
Outpatient
36%
Patient
100%
Patient Care
5%
Patient Characteristics
5%
Predictor
36%
Prevalence
36%
Psoriasis
73%
Psoriasis Area and Severity Index
16%
Psoriatic Arthritis
5%
Screening
8%
Skin
10%
Solid Organ Transplantation
18%
Squamous Cell Carcinoma
8%
Survival
36%
T Cell
6%
Therapeutic Procedure
38%
Treatment Response
5%
Nursing and Health Professions
Adalimumab
7%
Analysis
83%
Apremilast
36%
Biological Product
36%
Clinical Outcome
5%
Combination Therapy
36%
Diseases
13%
Drug
73%
Etanercept
7%
Female Patient
5%
Gender
7%
Hazard Ratio
7%
Interleukin 17 Antibody
36%
Ixekizumab
11%
Observation
5%
Patient
7%
Psoriasis
80%
Psoriasis Area and Severity Index
19%
Psoriatic Arthritis
12%
Secukinumab
11%
Survival
55%
Survival Rate
40%
Time
36%
Treatment Response
5%
Ustekinumab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
7%
Adverse Event
6%
Apremilast
36%
Biological Product
77%
Cohort Study
7%
Diseases
8%
Drug
80%
Etanercept
7%
Interleukin 17 Antibody
36%
Interleukin 23
10%
Interleukin 23 Antibody
36%
Interleukin 23p19
16%
Ixekizumab
11%
Psoriasis
84%
Psoriatic Arthritis
7%
Secukinumab
11%
Survival
55%
Survival Rate
40%
Ustekinumab
11%
